Startup Synchron specializes in implantable Brain Computer Interface (BCI) interfaces.
Synchron is based in Brooklyn, New York, and its R&D facilities are located in Melbourne, Australia.
Since 2012, the company has been developing a BCI platform that avoids the need for open surgery on brain with a minimally invasive procedure. Synchron Switch BCI received FDA Breakthrough Device Designation certification in 2020 and is undergoing human clinical trials in and for 2024 USA. Australia
Materials from Synchron are published in many well-known publications, including JAMA Neurology, Nature Biotechnology, Nature Biomedical Engineering and JNIS.
According to Tom Oxley, MD, CEO and founder of Synchron, the SWITCH study is a demonstration of the safety of using a commercial-level brain-computer interface on a small number of participants.
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |